Infringement Analysis in Philadelphia.

A patent infringement analysis Philadelphia companies rely on is built for a court that behaves unlike the famous patent forums, and for an industry base that is unlike almost anywhere else in the country. The suit that follows is filed in the U.S. District Court for the Eastern District of Pennsylvania, which sits at the James A. Byrne U.S. Courthouse on Market Street. It is a busy general-litigation district that, unusually for a patent hotspot, has adopted no local patent rules at all. And the technology on the claim chart is increasingly a living cell or a viral vector, because Philadelphia is the global center of cell and gene therapy. Both facts change how the analysis has to be built.

Why a patent infringement analysis Philadelphia case answers to the Eastern District

Start with the court, because it sets the timetable for everything that follows. A patent infringement suit filed in Philadelphia goes to the U.S. District Court for the Eastern District of Pennsylvania, known as the E.D. Pa., which sits at the James A. Byrne U.S. Courthouse at 601 Market Street and also maintains offices in Allentown, Reading and Easton. Its jurisdiction covers Philadelphia along with Berks, Bucks, Chester, Delaware, Lancaster, Lehigh, Montgomery and Northampton counties. It is one of the original districts created by the Judiciary Act of 1789.

Here is the fact that catches out-of-town counsel by surprise. Unlike the Western District of Texas, the Eastern District of Texas, or even the Western District of Pennsylvania across the state, the E.D. Pa. has adopted no local patent rules and no standing form scheduling order for patent cases. There is no automatic calendar of infringement contentions followed by invalidity contentions. Instead the deadlines are set case by case, by the assigned judge and the parties, under Federal Rules 1 and 16 at the Rule 16 conference.

That freedom is a trap for the unprepared. Because the disclosure schedule is negotiated rather than imposed, the party that walks into the scheduling conference with a finished, defensible infringement read controls the tempo. A thin analysis leaves you arguing for a slow calendar you did not want. A rigorous patent infringement analysis Philadelphia counsel can put on the table early is therefore not just evidence; it is leverage over the shape of the case.

One more jurisdictional point matters. The E.D. Pa. sits in the Third Circuit for most purposes, but patent appeals do not follow that path. Every patent appeal from this court, like every other district, goes to the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. The claim construction that governs your dispute is the Federal Circuit’s, not the Third Circuit’s.

TC Heartland, Delaware and where a Philadelphia defendant can be sued

The single most important venue rule for any Philadelphia business is TC Heartland LLC v. Kraft Foods Group Brands LLC, decided by the Supreme Court in 2017. It held that a domestic corporation “resides,” for patent-venue purposes, only in its state of incorporation. A patent owner can no longer sue a defendant in any district where its products happen to reach the market.

Under the patent venue statute, a suit must be brought either where the defendant resides, meaning its state of incorporation, or where it has committed acts of infringement and maintains a regular and established place of business. The Federal Circuit’s In re Cray decision set the working test: there must be a physical place in the district, it must be regular and established, and it must be the place of the defendant rather than merely of a home-working employee.

Philadelphia has a geography problem that makes this acute. Wilmington, Delaware sits barely thirty miles down I-95, and an enormous share of American companies, including many Philadelphia-headquartered ones, are incorporated in Delaware. For those defendants, the natural home forum for a patent suit is often the District of Delaware, not the E.D. Pa. So the first question in any analysis is which of the two neighbouring districts actually has venue.

For a defendant with real operations in the eight-county E.D. Pa. footprint, such as a lab in University City, a plant in Montgomery County or a headquarters on Market Street, venue here can attach even if incorporation is elsewhere. Mapping incorporation, facilities and sales presence across the Philadelphia-Wilmington corridor is a first step in the analysis, not an afterthought, because a misplaced case can lose a year to a transfer motion.

Building the claim chart: element-by-element evidence of use

The core of any infringement study is the claim chart, sometimes called an evidence-of-use or EoU chart. It places each limitation of an asserted claim in one column and the corresponding feature of the accused product or process in the next, with a cited source for every mapping. Infringement under 35 U.S.C. § 271 requires that every element of a claim be present, either literally or under the doctrine of equivalents. A single missing limitation defeats the claim entirely.

For Philadelphia’s technology base this is rarely a matter of reading a brochure. The accused subject matter may be a chemical process, an enterprise software platform, a medical device or a biologic manufacturing method, much of it proprietary and behind a plant fence or a clinical protocol. Public evidence, including datasheets, peer-reviewed papers, regulatory filings, FDA labels and conference presentations, has to be assembled into a credible mapping before discovery opens the internal detail.

Software and networked systems raise a further wrinkle. Much modern platform and health-data technology is claimed as methods executed across distributed actors, which implicates divided-infringement law: who performs each step, and does one party direct or control the others? A claim chart for such a system has to allocate each step to an actor, or the theory collapses under Akamai and the cases that followed it.

A rigorous chart typically covers, at minimum:

• Every limitation of every asserted claim, mapped to a specific accused feature
• A cited, verifiable source for each mapping, ranked by evidentiary strength
• An explicit note wherever the read depends on the doctrine of equivalents
• An actor allocation for each step of any method or system claim
• The gaps where public evidence runs out and discovery will be required

We build every chart to survive that scrutiny. Every limitation is mapped, every mapping is sourced, and the gaps are flagged rather than papered over, because that candour is what lets counsel decide whether to file, settle or fight.

Cellicon Valley: infringement analysis for cell and gene therapy

No other feature defines Philadelphia’s patent landscape like cell and gene therapy. The region is so central to the field that it has earned the nickname “Cellicon Valley,” and the label is earned. The first FDA-approved CAR-T cell therapy, Kymriah, came out of the University of Pennsylvania and Children’s Hospital of Philadelphia. So did Luxturna, the first FDA-approved gene therapy for an inherited disease, commercialised by Spark Therapeutics, a CHOP spin-out now part of the Roche group.

Penn Medicine ranks first among global universities for CAR-T cell patents, and the ecosystem around it, including Spark, Carisma, Cabaletta Bio, Passage Bio and a cluster of others, generates a dense and valuable patent estate. Spark is investing hundreds of millions in a Gene Therapy Innovation Center on Drexel’s campus. Where there is a concentration of foundational patents and fast-moving competitors, infringement disputes follow.

These matters do not fit the ordinary claim chart. The asserted patents often claim a viral vector construct, a cell-engineering method, a manufacturing process, or a method of treating a specific disease with an engineered cell. The accused “product” may be a living therapy administered once inside a hospital, which makes evidence of use a matter of clinical protocols, manufacturing records and FDA submissions rather than a teardown.

A patent infringement analysis Philadelphia gene-therapy companies commission therefore has to read like the science it describes. It maps vector sequences, promoter elements, transduction steps and dosing regimens against the claim language, and it treats the FDA-approved label and the published trial protocol as primary evidence. That is the level at which a district judge, or the Federal Circuit, will ultimately test the read.

Biologics, the BPCIA patent dance and FDA-label evidence

Philadelphia’s older pharmaceutical strength, anchored by large-molecule and biologics manufacturers across the region, brings a second and very particular kind of infringement analysis: the biosimilar dispute governed by the Biologics Price Competition and Innovation Act, the BPCIA. This is a statutory framework, not the ordinary path, and it shapes the analysis from the outset.

The BPCIA sets up the so-called “patent dance,” a structured exchange of the biosimilar applicant’s manufacturing information and the reference sponsor’s patent list, which narrows the asserted patents before any complaint is filed. An infringement analysis built for this process is really two analyses: one on the composition and manufacturing patents, and one on the method-of-treatment patents that protect how the biologic is used.

Method-of-treatment claims are where the evidence gets subtle. Because a biosimilar or generic maker does not itself treat patients, the sponsor usually cannot prove direct infringement and must argue induced infringement instead. The key evidence is frequently the defendant’s own FDA label, read for whether it instructs the patented use. The Federal Circuit’s GSK v. Teva decision showed that even a “skinny label” that carves out an indication can support induced infringement when press releases and marketing materials fill the gap.

That makes label analysis a technical discipline of its own. We compare the accused label, the carve-outs, and the surrounding promotional materials against each step of the asserted method claim, because in a Philadelphia biologics case the words on the package insert can decide the outcome as surely as the molecule inside it.

PTAB, invalidity and the two-sided nature of the work

An infringement analysis is only half the picture. The same claims you assert can be challenged for validity, and in the United States the sharpest tool for that is inter partes review before the Patent Trial and Appeal Board at the USPTO. An accused infringer will frequently answer an E.D. Pa. complaint by petitioning the PTAB to cancel the asserted claims over prior art, running that challenge in parallel with the district-court case.

That makes prior-art and validity work inseparable from infringement work. Before asserting a patent, a Philadelphia patent owner should know how its claims hold up against the closest prior art, because a successful IPR can end the case regardless of how strong the infringement read is. Before defending, an accused company should know whether an IPR petition is a faster, cheaper route to daylight than a jury trial on Market Street.

This is especially true in life sciences, where a foundational gene-therapy or antibody patent may face both an infringement assertion and a validity attack on written-description and enablement grounds. We therefore pair our infringement work with a hard look at validity, connecting it to a full prior art & litigation search and, where the exposure runs the other way, to a patent invalidation strategy built around the strongest references.

The two tracks eventually converge. The Federal Circuit hears appeals both from the E.D. Pa. and from the PTAB, so the same appellate bench reviews the district court’s claim construction and the Board’s patentability findings. An analysis that anticipates both from day one is worth far more than one rebuilt under two separate deadlines.

What Philadelphia’s other industries put on the chart

Life sciences lead, but they are not the whole docket. Philadelphia’s economy layers several patent-heavy sectors on top of one another, and each brings a different kind of accused technology to the analysis.

Pharmaceuticals and specialty chemicals come first after cell and gene therapy. The region has deep roots in small-molecule drugs, coatings, advanced materials and process chemistry, which produce formulation, polymorph and manufacturing-process disputes where the infringement read turns on analytical data rather than a visible feature. These charts lean on spectra, assays and process parameters.

Financial technology and enterprise software are the second stream. Philadelphia hosts major financial-services and health-insurance operations, along with a growing software sector, and the disputes here are classic system and method claims: payment processing, data security, claims adjudication and platform architecture. Divided infringement and § 101 eligibility questions attach to almost all of them.

The universities are the third force, and they run through everything. Penn, Drexel and Temple are not just talent pipelines; they are prolific patent owners and licensors, and their technology-transfer offices sit on one side or the other of many regional disputes. An analysis involving a university-originated patent has to account for licensing chains, government-funding march-in rights under Bayh-Dole, and joint-inventorship questions that a purely corporate patent rarely raises.

Across all of these, the common thread is technical density. A useful patent infringement analysis Philadelphia delivers is not a legal memo with a diagram attached; it is an engineering or scientific read of the accused technology, expressed in claim language, that a district judge or a PTAB panel can follow without a translator.

How we work with Philadelphia counsel and in-house teams

Most Philadelphia work reaches us in one of two postures: a patent owner weighing whether to assert, or a company that has just been accused and needs to understand its exposure quickly. Both start the same way, with the claims, the accused technology, and an honest map between them. We work from patents, product and clinical literature, FDA labels and submissions, source code under a protective order where it is available, and the peer-reviewed papers that Philadelphia’s researchers publish freely.

The deliverable is a claim chart and a written analysis that states the theory plainly: which claims read on the product, where the evidence is strong, where it depends on discovery, and where an equivalents, induced-infringement or divided-infringement argument is doing the heavy lifting. Where validity is the real battleground rather than infringement, we say so, and we scope the prior-art search that has to go with it.

Because the E.D. Pa. sets its schedule at the Rule 16 conference rather than by standing patent rules, timing is flexible but the advantage goes to whoever is ready first. We build the analysis to be filing-ready for that conference, so counsel can propose a calendar from strength rather than react to one.

Philadelphia runs on Eastern Time and sits inside the U.S. business day, so work coordinated with E.D. Pa. counsel, Delaware co-counsel, or PTAB teams in Washington moves within a single cycle. Where a deadline is fixed, whether a scheduling-order contention date, a BPCIA exchange or an IPR response, we prioritise the charts the date demands and follow with the remainder. The aim is an analysis counsel can file, not one they have to rebuild.

IP Landscape & Resources in Philadelphia

Key intellectual-property authorities and venues relevant to Philadelphia:

• United States Patent and Trademark Office — PTAB — grants U.S. patents and hosts the Patent Trial and Appeal Board, which decides inter partes review challenges to asserted claims
• U.S. District Court for the Eastern District of Pennsylvania — the federal court at the James A. Byrne U.S. Courthouse in Philadelphia that hears patent infringement suits filed in the region
• U.S. Court of Appeals for the Federal Circuit — hears all patent appeals from the E.D. Pa. and the PTAB, giving both tracks a single appellate forum
• U.S. International Trade Commission — Section 337 — investigates infringing imports and issues exclusion orders enforced at the border by U.S. Customs and Border Protection

Request a Patent Infringement Analysis Consultation in Philadelphia

Explore related PerspireIP services: Patent Infringement Analysis · patent invalidation · prior art & litigation search · our United States IP hub.

Frequently Asked Questions